Moomoo AI 已提取核心信息
On February 14, 2024, AbbVie Inc. announced a significant leadership transition with Robert A. Michael set to succeed Richard A. Gonzalez as Chief Executive Officer (CEO), effective July 1, 2024. Gonzalez, who has been at the helm since AbbVie's inception in 2013, will retire from his CEO role and take on the position of Executive Chairman of the Board. Michael, currently serving as AbbVie's President and Chief Operating Officer, has a long history with the company, having held various leadership roles since joining Abbott in 1993, which later became part of AbbVie. The Board of Directors has also appointed Michael as a Class II director on the Board, coinciding with his CEO appointment. The announcement was made through a press release issued on February...Show More
On February 14, 2024, AbbVie Inc. announced a significant leadership transition with Robert A. Michael set to succeed Richard A. Gonzalez as Chief Executive Officer (CEO), effective July 1, 2024. Gonzalez, who has been at the helm since AbbVie's inception in 2013, will retire from his CEO role and take on the position of Executive Chairman of the Board. Michael, currently serving as AbbVie's President and Chief Operating Officer, has a long history with the company, having held various leadership roles since joining Abbott in 1993, which later became part of AbbVie. The Board of Directors has also appointed Michael as a Class II director on the Board, coinciding with his CEO appointment. The announcement was made through a press release issued on February 20, 2024, and is part of a planned succession to ensure a smooth transition of leadership. The company's press release highlighted Michael's significant contributions to AbbVie, including his involvement in key business development opportunities and navigating the end of exclusivity for Humira in the U.S. Gonzalez's tenure as CEO saw the company's market capitalization increase substantially, and he will continue to offer his experience as Executive Chairman.
2024年2月14日，艾伯维公司宣布了重大的领导层交接，罗伯特·迈克尔将接替理查德·冈萨雷斯担任首席执行官（CEO），自2024年7月1日起生效。冈萨雷斯自2013年艾伯维成立以来一直掌舵，他将从首席执行官一职退休，担任董事会执行主席一职。迈克尔目前担任艾伯维总裁兼首席运营官，在公司有着悠久的历史，自1993年加入雅培以来，他曾担任过各种领导职务，雅培后来成为艾伯维的一员。董事会还任命Michael为董事会二类董事，恰逢其首席执行官的任命。该公告是通过2024年2月20日发布的新闻稿宣布的，是为确保领导层平稳过渡而计划继任的一部分。该公司的新闻稿强调了迈克尔对艾伯维的重大贡献，包括他参与关键业务发展机会以及为Humira在美国的独家经营权的终结做好准备。冈萨雷斯在担任首席执行官期间，公司的市值大幅增加，他将继续提供担任执行董事长的经验。
2024年2月14日，艾伯维公司宣布了重大的领导层交接，罗伯特·迈克尔将接替理查德·冈萨雷斯担任首席执行官（CEO），自2024年7月1日起生效。冈萨雷斯自2013年艾伯维成立以来一直掌舵，他将从首席执行官一职退休，担任董事会执行主席一职。迈克尔目前担任艾伯维总裁兼首席运营官，在公司有着悠久的历史，自1993年加入雅培以来，他曾担任过各种领导职务，雅培后来成为艾伯维的一员。董事会还任命Michael为董事会二类董事，恰逢其首席执行官的任命。该公告是通过2024年2月20日发布的新闻稿宣布的，是为确保领导层平稳过渡而计划继任的一部分。该公司的新闻稿强调了迈克尔对艾伯维的重大贡献，包括他参与关键业务发展机会以及为Humira在美国的独家经营权的终结做好准备。冈萨雷斯在担任首席执行官期间，公司的市值大幅增加，他将继续提供担任执行董事长的经验。
有用
没用